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Septum to puncture
(sec)43  40 22  22 0.02Puncture to cross (sec) 22  9 22  11 1
Absolute jPre-Postj
DifferenceSuperior Rim to TS site
(mm)0.8  0.9 1.0  1.2 0.24Inferior Rim to TS site
(mm)0.7  0.6 1.1  1.2 0.12Anterior Rim to TS site
(mm)1.8  2.0 1.4  1.6 0.45Posterior Rim to TS
site (mm)1.3  1.8 1.3  1.5 0.97Pre-to-max Tent TS
site (mm)4.7  3.0 2.8  2.8 0.02CONCLUSIONS Procedural times and degree of septum tenting
favored the RF over standard needle; however, accuracy was similar
with both approaches. RF was a successful strategy when standard
needle failed. There were no major complications with either TS
puncture strategy.
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Mitral Annular Calciﬁcation Does Not Impact MitraClip Procedural Success
and Is Not Associated with Durability of Repair
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BACKGROUND Mitral annular calciﬁcation (MAC) has been associated
with coronary atherosclerosis and increased mortality. While patients
(pts) undergoing percutaneous edge-to-edge repair of mitral regurgi-
tation (MR) often have signiﬁcant MAC, the impact of MAC on pro-
cedural success and durability of repair is not known.
METHODS Pts who underwent percutaneous repair of MR between
April 2009 and May 2014 with the MitraClip device (Abbott Vascular,
Santa Clara, CA) were included in the analysis. Procedural success was
deﬁned as a reduction of MR of 2 grades or more on transthoracic
echocardiogram done prior to discharge. A second metric of proce-
dural success was a reduction of MR to less than or equal to mild-to-
moderate. Durability of repair was deﬁned as successful retention of
procedural success at 1-yr transthoracic echocardiogram. Pts were
graded as having mild MAC if annular calciﬁcation involved one-third
or less of the posterior annulus, or moderate or severe if it involved
more. Procedural success was compared across severities of MAC, and
durability of repair was compared between pts with no or mild MAC
and those with moderate or severe MAC.
RESULTS 173 pts were included in the analysis. Mean age at percu-
taneous repair was 76.9  12.6 yrs and 40.8% were females. Hemo-
dialysis and coronary artery disease was present in 10/173 (5.8%) and
94/173 (54.3%) of pts, respectively. Pts with MAC were older 79.9 
10.1 vs. 74.3  14.0 yrs (p¼0.003). MR was moderate-to-severe in 35/
173 (20.2%) of pts and severe in 138/173 (79.8%) of pts. Procedural
success of reduction of MR of 2 grades or more was obtained in 81/87
(93.1%) pts with no MAC, 60/61 (98.4%) pts with mild MAC, and 24/25
(96.0%) pts with moderate or severe MAC (p¼0.321). At 1-yr follow-up
for those who obtained initial reduction of MR of 2 grades or more, pts
with no or mild MAC retained the reduction in 86/99 (86.9%) in-
stances, while pts with moderate or severe MAC retained the reduc-
tion in 14/15 (93.3%) instances (p¼0.690). Procedural success of
reduction of MR  mild-to-moderate was obtained in 69/87 (79.3%)
pts with no MAC, 52/61 (85.2%) pts with mild MAC, and 22/25 (88.0%)
pts with moderate-to-severe MAC (p¼0.481). At 1-yr follow up for
those who obtained initial reduction of MR  mild-to-moderate, pts
with no or mild MAC retained the reduction in 67/86 (77.9%) in-
stances, while pts with moderate or severe MAC retained the reduc-
tion in 11/14 (78.6%) instances (p¼1.000).
CONCLUSIONS MAC does not impact MitraClip procedural success in
percutaneous edge-to-edge MR repair despite increased age in ptswith MAC. Procedural success is high across MAC severities and MAC
alone should not preclude percutaneous edge-to-edge repair of MR.
Moreover, moderate or severe MAC, which may make surgical repair
of MR challenging, is not associated with decreased durability of
percutaneous repair. Further investigations are warranted to explore
this relationship.
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Immediate and long term outcomes after repeat percutaneous mitral
valvuloplasty for patients with mitral valve restenosis
Bahaa Alhabil1
1Institut Mutualiste Montsouris, Paris, HI
BACKGROUND Only rare reports have been published about redo
PMV and data regarding its long term safety and efﬁcacy are scarce. So
we decided to explore the immediate and long-term outcomes of
repeat (redo) percutaneous mitral valvuloplasty (PMV) in a series of
patients with mitral restenosis in comparison with initial PMV in the
same series and to determine prognostic factors of outcomes.
METHODS A retrospective study enrolling a population of 170 pa-
tients treated by PMV in the university hospital Habib Thameur,
Tunisia, between January 1997 and January 2011. The study group
consisted of 50 patients (mean age 4710 years) who underwent a
redo PMV. All redo PMV procedures were performed using the Inoue
balloon system. Procedural success was deﬁned as 50% or more in-
crease of mitral valve area (MVA) with a ﬁnal MVA 1.5 cm2, without
major complications. Restenosis was deﬁned as loss of >50% of the
initial gain of MVA by the preceding PMV with a ﬁnal MVA <1.5 cm2.
RESULTS Successful procedural result was achieved in 81.1% of pa-
tients. There were no in-hospital complications. Both the initial and
redo procedures were similar concerning the ﬁnal increase of mitral
valve area, the decrease of mean transmitral pressure gradient and the
mean pulmonary artery pressure (P<0.001 for all). The Procedural
success and the gain of MVA were higher in the initial as compared to
the redo procedure (P<0.05). The only independent predictor of redo
PMV success was an echocardiographic score <8. Early symptomatic
improvement after redo PMV of 1 NYHA functional class was ob-
tained in 95% of the patients. The mean follow-up was 80, 8535
months. There were no deaths and restenosis was noted in 40%. Eight
(16%) patients required mitral valve replacement (34.21 months after
redo PMV) due to recurrent symptoms. The predictive factors of
restenosis identiﬁed by the univariate analysis in our study were:
previous surgical commissurotomy (p¼0.01) and a high echocardio-
graphic score (p¼0.028).
CONCLUSIONS Repeat PMV is safe and provides good immediate re-
sults in patients with restenosis after successful ﬁrst procedure. Long-
term results of redo PMV are satisfactory and related mainly to the
echo score.
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BACKGROUND Percutaneous mitral valve repair (PMVR) using the
MitraClip-system has become a valid alternative for patients with
severe mitral regurgitation (MR) and high surgical risk. For a lack of
evidence deriving from randomized trials, data from high volume
registries is therefore of interest. Herein, we report the results of the
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try (MitraSwiss).
METHODS Consecutive patients with moderate to severe MR (3þ)
and high surgical risk (as discussed within a Heart-team) or
declined for surgical repair were included in the registry. PMVR was
performed under general anesthesia in the cath-lab or hybrid
operating room with ﬂuoroscopic and transesophageal echocardi-
ography guidance. Transthoracic echocardiography, 6-min walking
distance (6MWD), and a Minnesota Living With Heart Failure
(MLWHF) score were recorded at baseline and after 6 months (mo).
Clinical endpoints were analyzed after 6 mo and included death,
hospitalization for heart failure, surgical mitral valve repair/
replacement and “redo” PMVR.
RESULTS From 2011 until now, a total 490 consecutive patients
(mean age 7710 years; 37% female) underwent PMVR and were
included in the registry by 10 institutions. Left ventricular ejection
fraction (LVEF) was 46.416.6%. The origin of the MR was functional
in 53%, degenerative in 40% and mixed 7%. In 38% of the procedures,
1 clip was implanted, whereas in 50% of the interventions 2 clips and
in 10 % of the interventions  3 clips were necessary to achieve an
acute procedural success (APS) rate of 91% (placement of 1 clip;
discharge MR grade of 2þ). 30 days survival was 98% (95%CI: 96.2-
98.9%) and 6 mo survival was 93% (95%CI: 90.3-94.9%). At 6 mo
79.4% of the patients were in NYHA class 2 and 72.6% had MR
grade  2þ and signiﬁcant reduction in pulmonary pressure. 6MWD
improved from 332145m at baseline to 375137m at 6 mo (p< 0.001)
and the MLWHF score improved from 3520 points to 2419 points
(p< 0.001). The analysis of predictors for adverse outcome, as well as
12 mo and longer follow up periods will be available for the time of the
meeting.
CONCLUSIONS The results of the nationwide, prospective MitraSwiss
registry indicate that PMVR using the MitraClip-system, is safe, has a
high procedural success rate and provides durable reduction of MR
severity and improvement in symptoms, functional capacity and
quality of life.
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BACKGROUND Pulmonary hypertension (PH) is common in MR. A
previous trial demonstrated signiﬁcant hemodynamic improvement
after MitraClip therapy, but it was less effective than surgery and is a
potential cause of iatrogenic mitral stenosis. Clinical characteristics
associated with delta sPAP after MitraClip therapy are unknown. Theaim of the study was to evaluate the association between clinical
characteristics, including residual mitral regurgitation (MR), and the
decrease in systolic pulmonary artery pressure (delta sPAP) after
MitraClip therapy.
METHODS We retrospectively reviewed the records of 110 consecutive
patients undergoing MitraClip therapy. Patients were categorized ac-
cording to MR severity at one month.
RESULTS All patients had MR 3þ at baseline, and 90.9% were 2þ
MR at follow-up (P < 0.001). sPAP decreased while the transmitral
gradient (TMG) increased. Delta sPAP was attenuated in patients
with MR 3þ and 4þ at one month. Multivariate linear regression
analysis showed that male sex and baseline sPAP were directly
correlated with delta sPAP. Right ventricular diameter (RVD) 2,
delta TMG, and one-month MR severity were inversely correlated
with delta sPAP (analysis of variance P < 0.001, R2 ¼ 0.47). Kaplan-
Meier analysis showed highest survival probability in patient groups
that had the largest delta sPAP after MitraClip therapy (log rank test
p ¼ 0.041).
Table. Associations with a decrease in sPAP at 1 month after MitraClip therapy according to linear regression
analysisVariableUnivariate Multivariater p value b 95% CI p valueMale, % 0.178 0.063 0.166 0.226, 6.852 0.037Coronary artery
bypass graft, %0.176 0.066Atrial ﬁbrillation, % -0.170 0.076PISA, cm 0.257 0.012sPAP, mmHg 0.453 <0.001 0.457 0.254, 0.504 <0.001RVD2, mm -0.318 0.001 -0.308 -0.884,
-0.298<0.001MR severity at 1 month -0.239 0.012 -0.242 -6.311,
-1.4580.002Delta TMG, mmHg -0.258 0.007 -0.275 -1.853,
-0.5200.001Values are mean  standard deviation or n (%). CI, conﬁdence interval. MR, mitral regurgitation; PISA,
proximal isovelocity surface area; RVD, right ventricular diameter; sPAP, systolic pulmonary artery pressure;
TMG, transmitral gradient.CONCLUSIONS Male sex and baseline sPAP were positively corre-
lated, and RVD2, delta TMG, and MR severity were negatively corre-
lated, with a decrease in sPAP. These ﬁndings provide insight into the
